Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’ most-advanced program, AKY-1189, is a miniprotein radioconjugate targeting Nectin-4, with multi-indication potential across multiple tumor types, including locally advanced or metastatic urothelial cancer, breast cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, and head and neck cancer. Aktis’ second pipeline program, AKY-2519, is a miniprotein radioconjugate targeting B7-H3 expressing tumors, including prostate, lung and other solid tumors. Aktis has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis’ proprietary pipeline. We are seeking an Associate Director of Corporate Development. The Associate Director will lead high-impact contract negotiations, drive search and evaluation efforts, and develop actionable competitive intelligence. The ideal candidate combines a deep knowledge of the biotechnology and oncology spaces with strong analytical and communication skills. This role will work cross-functionally with R&D, CMC, G&A, and external legal counsel on a variety of initiatives. This position will report to the Executive Director of Corporate Development.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Education Level
Ph.D. or professional degree